Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26150601,response rate,The ACR20 response rate at week 24 in the per-protocol set was 78.1% for SB4 and 80.3% for ETN.,"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150601/),%,78.1,20731,DB00005,Etanercept
,26150601,response rate,The ACR20 response rate at week 24 in the per-protocol set was 78.1% for SB4 and 80.3% for ETN.,"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150601/),%,80.3,20732,DB00005,Etanercept
,12709725,apparent clearance,"The population mean apparent clearance was 0.117 L/h (95% CI, 0.108-0.130 L/h) for white female patients and 0.138 L/h (95% CI, 0.118-0.163 L/h) for white male patients.",Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709725/),[l] / [h],0.117,27208,DB00005,Etanercept
,12709725,apparent clearance,"The population mean apparent clearance was 0.117 L/h (95% CI, 0.108-0.130 L/h) for white female patients and 0.138 L/h (95% CI, 0.118-0.163 L/h) for white male patients.",Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709725/),[l] / [h],0.138,27209,DB00005,Etanercept
,12709725,absorption half-life,"The mean absorption half-life was 20.9 hours, and the elimination half-life was 95.4 hours.",Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709725/),h,20.9,27210,DB00005,Etanercept
,12709725,elimination half-life,"The mean absorption half-life was 20.9 hours, and the elimination half-life was 95.4 hours.",Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709725/),h,95.4,27211,DB00005,Etanercept
,26181632,half-life,Subcutaneously administered EC0565 in rats displayed good bioavailability and a relatively long half-life (~12 h).,Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26181632/),h,12,53303,DB00005,Etanercept
,22088414,T(max),"Both test and reference drugs were absorbed with a median T(max) of 72 (range, 36-144) hours and eliminated with mean (%CV) t(½) of 92.7 (20.9%) and 87.4 (16.6%) hours, respectively.","Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22088414/),h,72,78056,DB00005,Etanercept
,22088414,t(½),"Both test and reference drugs were absorbed with a median T(max) of 72 (range, 36-144) hours and eliminated with mean (%CV) t(½) of 92.7 (20.9%) and 87.4 (16.6%) hours, respectively.","Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22088414/),h,92.7,78057,DB00005,Etanercept
,22088414,t(½),"Both test and reference drugs were absorbed with a median T(max) of 72 (range, 36-144) hours and eliminated with mean (%CV) t(½) of 92.7 (20.9%) and 87.4 (16.6%) hours, respectively.","Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22088414/),h,87.4,78058,DB00005,Etanercept
,16995864,steady-state predose serum concentrations,The mean +/- SD steady-state predose serum concentrations of etanercept for the 25-mg BIW arm at 12 weeks in study 1 were 1590 +/- 885 ng ml(-1).,Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995864/),[ng] / [ml],1590,93973,DB00005,Etanercept
,16995864,steady-state concentrations,"In study 2, mean +/- SD etanercept steady-state concentrations at 12 weeks were 1900 +/- 1110 ng ml(-1) in the 25-mg BIW group and 3830 +/- 1870 ng ml(-1) in the 50-mg BIW group.",Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995864/),[ng] / [ml],1900,93974,DB00005,Etanercept
,16995864,steady-state concentrations,"In study 2, mean +/- SD etanercept steady-state concentrations at 12 weeks were 1900 +/- 1110 ng ml(-1) in the 25-mg BIW group and 3830 +/- 1870 ng ml(-1) in the 50-mg BIW group.",Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995864/),[ng] / [ml],3830,93975,DB00005,Etanercept
,16995864,steady-state predose serum concentrations,"The mean +/- SD steady-state predose serum concentrations of etanercept at 12 weeks in study 3 were 768 +/- 475 ng ml(-1) for the 25-mg QW regimen, 1990 +/- 1030 ng ml(-1) for the 25-mg BIW regimen and 4020 +/- 2100 ng ml(-1) for the 50-mg BIW regimen.",Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995864/),[ng] / [ml],768,93976,DB00005,Etanercept
,16995864,steady-state predose serum concentrations,"The mean +/- SD steady-state predose serum concentrations of etanercept at 12 weeks in study 3 were 768 +/- 475 ng ml(-1) for the 25-mg QW regimen, 1990 +/- 1030 ng ml(-1) for the 25-mg BIW regimen and 4020 +/- 2100 ng ml(-1) for the 50-mg BIW regimen.",Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995864/),[ng] / [ml],1990,93977,DB00005,Etanercept
,16995864,steady-state predose serum concentrations,"The mean +/- SD steady-state predose serum concentrations of etanercept at 12 weeks in study 3 were 768 +/- 475 ng ml(-1) for the 25-mg QW regimen, 1990 +/- 1030 ng ml(-1) for the 25-mg BIW regimen and 4020 +/- 2100 ng ml(-1) for the 50-mg BIW regimen.",Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995864/),[ng] / [ml],4020,93978,DB00005,Etanercept
,32108909,plasma half-life,"At a dose level of 20.6 mg kg-1, the antibody had a plasma half-life of 210 h.",Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32108909/),h,210,94029,DB00005,Etanercept
,15831771,time to peak concentration,"Etanercept is absorbed slowly from the site of subcutaneous injection, with time to peak concentration at approximately 48 to 60 hours, and is cleared slowly from the body with a t(1/2) of 70 to 100 hours.",Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),h,48 to 60,95896,DB00005,Etanercept
,15831771,t(1/2),"Etanercept is absorbed slowly from the site of subcutaneous injection, with time to peak concentration at approximately 48 to 60 hours, and is cleared slowly from the body with a t(1/2) of 70 to 100 hours.",Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),h,70 to 100,95897,DB00005,Etanercept
,15831771,absolute bioavailability,The absolute bioavailability of etanercept was 58% in healthy subjects following subcutaneous administration.,Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),%,58,95898,DB00005,Etanercept
,16554449,time to maximum serum concentration,"Etanercept was slowly absorbed, with mean+/-SD time to maximum serum concentration of 47+/-15 hours (J), and 51+/-20 hours (A).",The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554449/),h,47,105558,DB00005,Etanercept
,16554449,time to maximum serum concentration,"Etanercept was slowly absorbed, with mean+/-SD time to maximum serum concentration of 47+/-15 hours (J), and 51+/-20 hours (A).",The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554449/),h,51,105559,DB00005,Etanercept
,16554449,half-life,"Etanercept was slowly eliminated, with observed mean+/-SD half-life of 80+/-25 hours (J) and 75+/-15 hours (A) and mean+/-SD apparent clearance of 144+/-65 mL/h (J) and 132+/-74 mL/h (A).",The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554449/),h,80,105560,DB00005,Etanercept
,16554449,half-life,"Etanercept was slowly eliminated, with observed mean+/-SD half-life of 80+/-25 hours (J) and 75+/-15 hours (A) and mean+/-SD apparent clearance of 144+/-65 mL/h (J) and 132+/-74 mL/h (A).",The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554449/),h,75,105561,DB00005,Etanercept
,16554449,apparent clearance,"Etanercept was slowly eliminated, with observed mean+/-SD half-life of 80+/-25 hours (J) and 75+/-15 hours (A) and mean+/-SD apparent clearance of 144+/-65 mL/h (J) and 132+/-74 mL/h (A).",The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554449/),[ml] / [h],144,105562,DB00005,Etanercept
,16554449,apparent clearance,"Etanercept was slowly eliminated, with observed mean+/-SD half-life of 80+/-25 hours (J) and 75+/-15 hours (A) and mean+/-SD apparent clearance of 144+/-65 mL/h (J) and 132+/-74 mL/h (A).",The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554449/),[ml] / [h],132,105563,DB00005,Etanercept
,29259050,response rates,ACR20 response rates at week 24 were similar between the groups (LBEC0101 93.3% vs ETN-RP 86.7%).,"Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29259050/),%,93.3,105788,DB00005,Etanercept
,29259050,response rates,ACR20 response rates at week 24 were similar between the groups (LBEC0101 93.3% vs ETN-RP 86.7%).,"Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29259050/),%,86.7,105789,DB00005,Etanercept
,25834031,tissue/plasma area under the concentration curve [AUC] ratios,"Etanercept exhibited modest tissue access (tissue/plasma area under the concentration curve [AUC] ratios 0.03-0.15 and estimated tissue reflection coefficients [σ] of 0.6-1.0), but with good penetration into arthritic paws (tissue/plasma AUC ratio 0.23 and σ 0.36).",Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.03-0.15,111091,DB00005,Etanercept
,25834031,tissue reflection coefficients [σ],"Etanercept exhibited modest tissue access (tissue/plasma area under the concentration curve [AUC] ratios 0.03-0.15 and estimated tissue reflection coefficients [σ] of 0.6-1.0), but with good penetration into arthritic paws (tissue/plasma AUC ratio 0.23 and σ 0.36).",Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.6-1.0,111092,DB00005,Etanercept
,25834031,tissue/plasma AUC ratio,"Etanercept exhibited modest tissue access (tissue/plasma area under the concentration curve [AUC] ratios 0.03-0.15 and estimated tissue reflection coefficients [σ] of 0.6-1.0), but with good penetration into arthritic paws (tissue/plasma AUC ratio 0.23 and σ 0.36).",Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.23,111093,DB00005,Etanercept
,25834031,tissue,Etanercept exposure in the inflamed paws of CIA rats was approximately 3-fold higher than in normal paws taken from either CIA or healthy rats (tissue/plasma AUC ratios 0.23 versus 0.07 and σ 0.36 versus 0.71).,Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.23,111094,DB00005,Etanercept
,25834031,AUC ratios,Etanercept exposure in the inflamed paws of CIA rats was approximately 3-fold higher than in normal paws taken from either CIA or healthy rats (tissue/plasma AUC ratios 0.23 versus 0.07 and σ 0.36 versus 0.71).,Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.23,111095,DB00005,Etanercept
,25834031,AUC ratios,Etanercept exposure in the inflamed paws of CIA rats was approximately 3-fold higher than in normal paws taken from either CIA or healthy rats (tissue/plasma AUC ratios 0.23 versus 0.07 and σ 0.36 versus 0.71).,Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.07,111096,DB00005,Etanercept
,25834031,σ,Etanercept exposure in the inflamed paws of CIA rats was approximately 3-fold higher than in normal paws taken from either CIA or healthy rats (tissue/plasma AUC ratios 0.23 versus 0.07 and σ 0.36 versus 0.71).,Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.36,111097,DB00005,Etanercept
,25834031,σ,Etanercept exposure in the inflamed paws of CIA rats was approximately 3-fold higher than in normal paws taken from either CIA or healthy rats (tissue/plasma AUC ratios 0.23 versus 0.07 and σ 0.36 versus 0.71).,Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834031/),,0.71,111098,DB00005,Etanercept
,28691952,trough concentration,"The mean etanercept trough concentration for each patient ranged from 0.7 to 6.8 mcg/mL, with a median trough concentration of 2.7 mcg/mL.",Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28691952/),[mcg] / [ml],0.7 to 6.8,111500,DB00005,Etanercept
,28691952,trough concentration,"The mean etanercept trough concentration for each patient ranged from 0.7 to 6.8 mcg/mL, with a median trough concentration of 2.7 mcg/mL.",Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28691952/),[mcg] / [ml],2.7,111501,DB00005,Etanercept
,28691952,trough concentrations,"Patients with an IPV above the median had lower mean etanercept trough concentrations compared to patients with an IPV below the median (1.96 mcg/mL, 95% CI, 1.7-2.4 versus 3.2 mcg/mL, 95% CI, 2.7-4.0; P = 0.001).",Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28691952/),[mcg] / [ml],1.96,111502,DB00005,Etanercept
,28691952,trough concentrations,"Patients with an IPV above the median had lower mean etanercept trough concentrations compared to patients with an IPV below the median (1.96 mcg/mL, 95% CI, 1.7-2.4 versus 3.2 mcg/mL, 95% CI, 2.7-4.0; P = 0.001).",Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28691952/),[mcg] / [ml],3.2,111503,DB00005,Etanercept
,24786016,CL/F,"A higher CL/F was noted in RA patients compared with that of the healthy Chinese subjects (1.64 L/h vs. 1.10 L/h), and a lower Ka was noticed in the RA patients compared with that of the healthy subjects (0.0317 h-1 vs. 0.0605 h-1).",Population pharmacokinetics of rhTNFR-Fc in Chinese patients with rheumatic arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786016/),[l] / [h],1.64,121066,DB00005,Etanercept
,24786016,CL/F,"A higher CL/F was noted in RA patients compared with that of the healthy Chinese subjects (1.64 L/h vs. 1.10 L/h), and a lower Ka was noticed in the RA patients compared with that of the healthy subjects (0.0317 h-1 vs. 0.0605 h-1).",Population pharmacokinetics of rhTNFR-Fc in Chinese patients with rheumatic arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786016/),[l] / [h],1.10,121067,DB00005,Etanercept
,24786016,Ka,"A higher CL/F was noted in RA patients compared with that of the healthy Chinese subjects (1.64 L/h vs. 1.10 L/h), and a lower Ka was noticed in the RA patients compared with that of the healthy subjects (0.0317 h-1 vs. 0.0605 h-1).",Population pharmacokinetics of rhTNFR-Fc in Chinese patients with rheumatic arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786016/),1/[h],0.0317,121068,DB00005,Etanercept
,24786016,Ka,"A higher CL/F was noted in RA patients compared with that of the healthy Chinese subjects (1.64 L/h vs. 1.10 L/h), and a lower Ka was noticed in the RA patients compared with that of the healthy subjects (0.0317 h-1 vs. 0.0605 h-1).",Population pharmacokinetics of rhTNFR-Fc in Chinese patients with rheumatic arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786016/),1/[h],0.0605,121069,DB00005,Etanercept
,20953211,CL/F,"The outcome parameters were CL/F (female: 0.168 L/h, male: 0.110 L/h), the apparent volume of distribution (Vd/F: 15.5 L), the absorption rate constant (Ka) (single dosage: 0.0605 h⁻¹, multiple dosage: 0.0408 h⁻¹), and the lag time (T(lag): 1.03 h).",Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953211/),[l] / [h],0.168,124374,DB00005,Etanercept
,20953211,CL/F,"The outcome parameters were CL/F (female: 0.168 L/h, male: 0.110 L/h), the apparent volume of distribution (Vd/F: 15.5 L), the absorption rate constant (Ka) (single dosage: 0.0605 h⁻¹, multiple dosage: 0.0408 h⁻¹), and the lag time (T(lag): 1.03 h).",Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953211/),[l] / [h],0.110,124375,DB00005,Etanercept
,20953211,apparent volume of distribution (Vd/F,"The outcome parameters were CL/F (female: 0.168 L/h, male: 0.110 L/h), the apparent volume of distribution (Vd/F: 15.5 L), the absorption rate constant (Ka) (single dosage: 0.0605 h⁻¹, multiple dosage: 0.0408 h⁻¹), and the lag time (T(lag): 1.03 h).",Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953211/),l,15.5,124376,DB00005,Etanercept
,20953211,absorption rate constant (Ka),"The outcome parameters were CL/F (female: 0.168 L/h, male: 0.110 L/h), the apparent volume of distribution (Vd/F: 15.5 L), the absorption rate constant (Ka) (single dosage: 0.0605 h⁻¹, multiple dosage: 0.0408 h⁻¹), and the lag time (T(lag): 1.03 h).",Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953211/),h⁻¹,0.0605,124377,DB00005,Etanercept
,20953211,absorption rate constant (Ka),"The outcome parameters were CL/F (female: 0.168 L/h, male: 0.110 L/h), the apparent volume of distribution (Vd/F: 15.5 L), the absorption rate constant (Ka) (single dosage: 0.0605 h⁻¹, multiple dosage: 0.0408 h⁻¹), and the lag time (T(lag): 1.03 h).",Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953211/),h⁻¹,0.0408,124378,DB00005,Etanercept
,20953211,lag time (T(lag),"The outcome parameters were CL/F (female: 0.168 L/h, male: 0.110 L/h), the apparent volume of distribution (Vd/F: 15.5 L), the absorption rate constant (Ka) (single dosage: 0.0605 h⁻¹, multiple dosage: 0.0408 h⁻¹), and the lag time (T(lag): 1.03 h).",Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20953211/),h,1.03,124379,DB00005,Etanercept
,25725773,time to reach the peak drug concentration [T max],"Intravenous and subcutaneous administration of 2 mg/kg of etanercept to rats showed that etanercept was slowly absorbed (time to reach the peak drug concentration [T max] = 1.60 days, bioavailability [F] = 47.18 %) and slowly eliminated (half-life [t 1/2], 2.33 days after intravenous administration and 3.31 days after subcutaneous administration).","Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),d,1.60,140326,DB00005,Etanercept
,25725773,bioavailability [F],"Intravenous and subcutaneous administration of 2 mg/kg of etanercept to rats showed that etanercept was slowly absorbed (time to reach the peak drug concentration [T max] = 1.60 days, bioavailability [F] = 47.18 %) and slowly eliminated (half-life [t 1/2], 2.33 days after intravenous administration and 3.31 days after subcutaneous administration).","Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),%,47.18,140327,DB00005,Etanercept
,25725773,half-life [t 1/2],"Intravenous and subcutaneous administration of 2 mg/kg of etanercept to rats showed that etanercept was slowly absorbed (time to reach the peak drug concentration [T max] = 1.60 days, bioavailability [F] = 47.18 %) and slowly eliminated (half-life [t 1/2], 2.33 days after intravenous administration and 3.31 days after subcutaneous administration).","Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),d,2.33,140328,DB00005,Etanercept
,25725773,half-life [t 1/2],"Intravenous and subcutaneous administration of 2 mg/kg of etanercept to rats showed that etanercept was slowly absorbed (time to reach the peak drug concentration [T max] = 1.60 days, bioavailability [F] = 47.18 %) and slowly eliminated (half-life [t 1/2], 2.33 days after intravenous administration and 3.31 days after subcutaneous administration).","Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),d,3.31,140329,DB00005,Etanercept
,25725773,area under the curve values on day 13 (AUC13day),"The area under the curve values on day 13 (AUC13day) were 121.25 ± 14.37 and 48.56 ± 6.78 μg day/mL after intravenous and subcutaneous administration, respectively.","Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),[d·μg] / [ml],121.25,140330,DB00005,Etanercept
,25725773,area under the curve values on day 13 (AUC13day),"The area under the curve values on day 13 (AUC13day) were 121.25 ± 14.37 and 48.56 ± 6.78 μg day/mL after intravenous and subcutaneous administration, respectively.","Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),[d·μg] / [ml],48.56,140331,DB00005,Etanercept
,25725773,V max,A two-compartment model with Michaelis-Menten elimination kinetics (V max = 94.28 µg/day; K m = 10.88 µg/mL) was used to describe the pharmacokinetic profile of etanercept.,"Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),[μg] / [d],94.28,140332,DB00005,Etanercept
,25725773,K m,A two-compartment model with Michaelis-Menten elimination kinetics (V max = 94.28 µg/day; K m = 10.88 µg/mL) was used to describe the pharmacokinetic profile of etanercept.,"Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725773/),[μg] / [ml],10.88,140333,DB00005,Etanercept
,19729904,ultrafilt,"CVVH was performed using polyacrylonitrile, polysulfone, and polymethylmethacrylate filters at 3 l/h ultrafiltrate and 200 ml/min blood flow rates.",Etanercept clearance during an in vitro model of continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729904/),l,3,162254,DB00005,Etanercept
,19729904,blood flow,"CVVH was performed using polyacrylonitrile, polysulfone, and polymethylmethacrylate filters at 3 l/h ultrafiltrate and 200 ml/min blood flow rates.",Etanercept clearance during an in vitro model of continuous venovenous hemofiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729904/),l,3,162255,DB00005,Etanercept
,19729904,ultrafilt,"CVVH was performed using polyacrylonitrile, polysulfone, and polymethylmethacrylate filters at 3 l/h ultrafiltrate and 200 ml/min blood flow rates.",Etanercept clearance during an in vitro model of continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729904/),m,200,162256,DB00005,Etanercept
,19729904,blood flow,"CVVH was performed using polyacrylonitrile, polysulfone, and polymethylmethacrylate filters at 3 l/h ultrafiltrate and 200 ml/min blood flow rates.",Etanercept clearance during an in vitro model of continuous venovenous hemofiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729904/),m,200,162257,DB00005,Etanercept
,19729904,sieving coefficient,Urea sieving coefficient remained constant (1.04 +/- 0.01).,Etanercept clearance during an in vitro model of continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729904/),,1.04,162258,DB00005,Etanercept
<,19729904,si,Ultrafiltrate etanercept concentrations were undetectable (sieving coefficient < 0.02) and transmembrane and adsorptive clearances were negligible.,Etanercept clearance during an in vitro model of continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729904/),,0.02,162259,DB00005,Etanercept
,16222785,apparent steady state clearance,The population mean of the apparent steady state clearance in males was 0.129 l/h. compared to 0.148 l/h in females.,Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16222785/),[l] / [h],0.129,174750,DB00005,Etanercept
,16222785,apparent steady state clearance,The population mean of the apparent steady state clearance in males was 0.129 l/h. compared to 0.148 l/h in females.,Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16222785/),[l] / [h],0.148,174751,DB00005,Etanercept
,16222785,apparent volume of distribution,"The population mean of the apparent volume of distribution also varied with time and was 16.11 during week 1, 20.01 during weeks 2-4 and 22.51 after week 4.",Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16222785/),,16.11,174752,DB00005,Etanercept
,16222785,apparent volume of distribution,"The population mean of the apparent volume of distribution also varied with time and was 16.11 during week 1, 20.01 during weeks 2-4 and 22.51 after week 4.",Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16222785/),,20.01,174753,DB00005,Etanercept
,16222785,apparent volume of distribution,"The population mean of the apparent volume of distribution also varied with time and was 16.11 during week 1, 20.01 during weeks 2-4 and 22.51 after week 4.",Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16222785/),,22.51,174754,DB00005,Etanercept
,10676822,time of peak concentration,Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L.,The pharmacokinetics of etanercept in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676822/),h,51,180986,DB00005,Etanercept
,10676822,peak concentration,Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L.,The pharmacokinetics of etanercept in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676822/),[mg] / [l],1.46,180987,DB00005,Etanercept
,10676822,AUC,"The AUC was 235 +/-98 mg x h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours.",The pharmacokinetics of etanercept in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676822/),[h·mg] / [l],235,180988,DB00005,Etanercept
,10676822,apparent clearance,"The AUC was 235 +/-98 mg x h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours.",The pharmacokinetics of etanercept in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676822/),[ml] / [h],132,180989,DB00005,Etanercept
,10676822,apparent volume of distribution,"The AUC was 235 +/-98 mg x h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours.",The pharmacokinetics of etanercept in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676822/),l,12,180990,DB00005,Etanercept
,10676822,half-life,"The AUC was 235 +/-98 mg x h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours.",The pharmacokinetics of etanercept in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676822/),h,68,180991,DB00005,Etanercept
,15703360,CL/F,"The following population PK model could adequately describe etanercept PK profiles for twice-weekly SC dosing of 0.4 mg/kg: CL/F (L/h)=0.0576 (female) or 0.0772 (male) x (body surface area in m2/1.071)1.41, V/F(L)=7.88 x (body weight in kg/30.8).",Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703360/),[l] / [h],0,192794,DB00005,Etanercept
,15703360,trough concentrations,"The means +/- standard deviations of simulated trough concentrations for 0.8-mg/kg once-weekly and 0.4-mg/kg twice-weekly dosing regimens were 1.58 +/- 1.07 mg/L and 1.92 +/- 1.09 mg/L, respectively.",Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703360/),[mg] / [l],1.58,192795,DB00005,Etanercept
,15703360,trough concentrations,"The means +/- standard deviations of simulated trough concentrations for 0.8-mg/kg once-weekly and 0.4-mg/kg twice-weekly dosing regimens were 1.58 +/- 1.07 mg/L and 1.92 +/- 1.09 mg/L, respectively.",Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703360/),[mg] / [l],1.92,192796,DB00005,Etanercept
,15703360,Peaks,Peaks during 0.8-mg/kg once-weekly dosing (2.92 +/- 1.41 mg/L) were only 11% higher than during 0.4 mg/kg twice-weekly dosing (2.62 +/- 1.23 mg/L).,Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703360/),[mg] / [l],2.92,192797,DB00005,Etanercept
,15703360,Peaks,Peaks during 0.8-mg/kg once-weekly dosing (2.92 +/- 1.41 mg/L) were only 11% higher than during 0.4 mg/kg twice-weekly dosing (2.62 +/- 1.23 mg/L).,Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15703360/),[mg] / [l],2.62,192798,DB00005,Etanercept
,15496641,clearance (CL,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.072,203962,DB00005,Etanercept
,15496641,volume of distribution in the central compartment (V(c),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),l,5.97,203963,DB00005,Etanercept
,15496641,volume of distribution in the peripheral compartment (V(p),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),l,2.05,203964,DB00005,Etanercept
,15496641,intercompartment clearance (Q,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.0645,203965,DB00005,Etanercept
,15496641,first-order absorption rate constant (k(a),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[1] / [h],0.0282,203966,DB00005,Etanercept
,15496641,absolute bioavailability,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),,0.626,203967,DB00005,Etanercept
,15496641,clearance,"Based on the bioequivalence criteria, the Bayesian-estimated clearance for patients receiving etanercept alone (mean: 0.070 L/h) was comparable to that for patients receiving a combination of etanercept and methotrexate (mean = 0.066 L/h).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.070,203968,DB00005,Etanercept
,15496641,clearance,"Based on the bioequivalence criteria, the Bayesian-estimated clearance for patients receiving etanercept alone (mean: 0.070 L/h) was comparable to that for patients receiving a combination of etanercept and methotrexate (mean = 0.066 L/h).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.066,203969,DB00005,Etanercept
,28639118,Tmax,T0001 was slowly absorbed with a median Tmax of 84 h and slowly eliminated with a T1/2Z of 42.1-58.2 h.,"Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNFα fusion protein, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639118/),h,84,210652,DB00005,Etanercept
,28639118,T1/2Z,T0001 was slowly absorbed with a median Tmax of 84 h and slowly eliminated with a T1/2Z of 42.1-58.2 h.,"Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNFα fusion protein, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28639118/),h,42.1-58.2,210653,DB00005,Etanercept
,22515513,C(max),"The C(max) and AUC(0-t) values of the reference product (mean ± standard deviation) were 1.25 ± 0.45 mg/L and 283.15 ± 98.57 mg*h/L, respectively, while those of the test drug were 1.35 ± 0.47 mg/L and 315.78 ± 99.38 mg*h/L, respectively.","Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515513/),[mg] / [l],1.25,211754,DB00005,Etanercept
,22515513,C(max),"The C(max) and AUC(0-t) values of the reference product (mean ± standard deviation) were 1.25 ± 0.45 mg/L and 283.15 ± 98.57 mg*h/L, respectively, while those of the test drug were 1.35 ± 0.47 mg/L and 315.78 ± 99.38 mg*h/L, respectively.","Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515513/),[mg] / [l],1.35,211755,DB00005,Etanercept
,22515513,AUC(0-t),"The C(max) and AUC(0-t) values of the reference product (mean ± standard deviation) were 1.25 ± 0.45 mg/L and 283.15 ± 98.57 mg*h/L, respectively, while those of the test drug were 1.35 ± 0.47 mg/L and 315.78 ± 99.38 mg*h/L, respectively.","Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515513/),[h·mg] / [l],283.15,211756,DB00005,Etanercept
,22515513,AUC(0-t),"The C(max) and AUC(0-t) values of the reference product (mean ± standard deviation) were 1.25 ± 0.45 mg/L and 283.15 ± 98.57 mg*h/L, respectively, while those of the test drug were 1.35 ± 0.47 mg/L and 315.78 ± 99.38 mg*h/L, respectively.","Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515513/),[h·mg] / [l],315.78,211757,DB00005,Etanercept
,28361455,entrapment efficiency,"MTX+ET-ALNE was characterized on the basis of particle size (410 ± 25.4 nm), PDI (0.160), and zeta potential (+38.6 ± 5.6 mV) and evaluated for pH (6.15), drug content (97.7 ± 2.17%), entrapment efficiency (76 ± 4.6%), in vitro release, and in vitro cytotoxicity.","Development of Albumin Coupled, Cholesterol Stabilized, Lipid Nanoemulsion of Methotrexate, and TNF-α Inhibitor for Improved In Vivo Efficacy Against Rheumatoid Arthritis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28361455/),%,76,220938,DB00005,Etanercept
,32720159,bioavailability,Model-based SC bioavailability of etanercept was 65.2% in the control group.,Lymphatic Distribution of Etanercept Following Intravenous and Subcutaneous Delivery to Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32720159/),%,65.2,248242,DB00005,Etanercept
,26680321,recovery,"The intra- and inter-assay relative standard deviation ranged from 3.9 to 12.2% and 6.2 to 11.1%, respectively, and recovery varied between 90.1 and 99.7%, confirming the assay's reliability.",Development of a sensitive enzyme-linked immunosorbent assay for the measurement of biologically active etanercept in patients with ankylosing spondylitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26680321/),,90,261952,DB00005,Etanercept
,28892591,half-maximal-effect concentration,"Empiric application of a maximal-effect (Emax ) model to pooled steady-state concentrations (Css ) and PD markers provided half-maximal-effect concentration estimates of 567, 573, 465, 87, and 159 ng/mL for change from baseline in number of swollen joints, number of painful joints, erythrocyte sedimentation rate, interleukin-6, and matrix metalloproteinase-3, respectively.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],567,264455,DB00005,Etanercept
,28892591,half-maximal-effect concentration,"Empiric application of a maximal-effect (Emax ) model to pooled steady-state concentrations (Css ) and PD markers provided half-maximal-effect concentration estimates of 567, 573, 465, 87, and 159 ng/mL for change from baseline in number of swollen joints, number of painful joints, erythrocyte sedimentation rate, interleukin-6, and matrix metalloproteinase-3, respectively.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],57,264456,DB00005,Etanercept
,28892591,half-maximal-effect concentration,"Empiric application of a maximal-effect (Emax ) model to pooled steady-state concentrations (Css ) and PD markers provided half-maximal-effect concentration estimates of 567, 573, 465, 87, and 159 ng/mL for change from baseline in number of swollen joints, number of painful joints, erythrocyte sedimentation rate, interleukin-6, and matrix metalloproteinase-3, respectively.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],3,264457,DB00005,Etanercept
,28892591,half-maximal-effect concentration,"Empiric application of a maximal-effect (Emax ) model to pooled steady-state concentrations (Css ) and PD markers provided half-maximal-effect concentration estimates of 567, 573, 465, 87, and 159 ng/mL for change from baseline in number of swollen joints, number of painful joints, erythrocyte sedimentation rate, interleukin-6, and matrix metalloproteinase-3, respectively.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],465,264458,DB00005,Etanercept
,28892591,half-maximal-effect concentration,"Empiric application of a maximal-effect (Emax ) model to pooled steady-state concentrations (Css ) and PD markers provided half-maximal-effect concentration estimates of 567, 573, 465, 87, and 159 ng/mL for change from baseline in number of swollen joints, number of painful joints, erythrocyte sedimentation rate, interleukin-6, and matrix metalloproteinase-3, respectively.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],87,264459,DB00005,Etanercept
,28892591,half-maximal-effect concentration,"Empiric application of a maximal-effect (Emax ) model to pooled steady-state concentrations (Css ) and PD markers provided half-maximal-effect concentration estimates of 567, 573, 465, 87, and 159 ng/mL for change from baseline in number of swollen joints, number of painful joints, erythrocyte sedimentation rate, interleukin-6, and matrix metalloproteinase-3, respectively.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],159,264460,DB00005,Etanercept
>,28892591,Css,"Css >∼2,000 ng/mL did not appear to offer additional benefit.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],"∼2,000",264461,DB00005,Etanercept
,28892591,Css,"It was concluded that the middle doses, 10 mg twice-weekly, 50 mg every 2 weeks, and 50 mg once-weekly, would provide Css in the target range of 500-2,000 ng/mL.",A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892591/),[ng] / [ml],"500-2,000",264462,DB00005,Etanercept
,15176649,clearance,"The mean Bayesian-predicted etanercept clearance and steady-state trough concentration were 0.072 l/h and 2,004 ng/ml, respectively.",Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176649/),[l] / [h],0.072,269102,DB00005,Etanercept
,15176649,steady-state trough concentration,"The mean Bayesian-predicted etanercept clearance and steady-state trough concentration were 0.072 l/h and 2,004 ng/ml, respectively.",Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176649/),[ng] / [ml],"2,004",269103,DB00005,Etanercept
,32200659,AUC0-∞,"The main pharmacokinetic parameters of QL0902 were as follows: AUC0-∞ was 461861.60 ± 126861.42 (h*ng/mL), AUC0-t was 453304.68 ± 124424.94 (h*ng/mL), Cmax was (2634.03 ± 833.82)ng/mL; The main pharmacokinetic parameters of reference Etanercept were as follows: AUC0-∞ was 537977.72 ± 153295.70 (h*ng/mL), AUC0-t was 528817.19 ± 150910.05 (h*ng/mL), Cmax was (2874.21 ± 822.31) ng/mL.","QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200659/),,461861.60,272137,DB00005,Etanercept
,32200659,AUC0-t,"The main pharmacokinetic parameters of QL0902 were as follows: AUC0-∞ was 461861.60 ± 126861.42 (h*ng/mL), AUC0-t was 453304.68 ± 124424.94 (h*ng/mL), Cmax was (2634.03 ± 833.82)ng/mL; The main pharmacokinetic parameters of reference Etanercept were as follows: AUC0-∞ was 537977.72 ± 153295.70 (h*ng/mL), AUC0-t was 528817.19 ± 150910.05 (h*ng/mL), Cmax was (2874.21 ± 822.31) ng/mL.","QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200659/),[h·ng] / [ml],453304.68,272138,DB00005,Etanercept
,32200659,Cmax,"The main pharmacokinetic parameters of QL0902 were as follows: AUC0-∞ was 461861.60 ± 126861.42 (h*ng/mL), AUC0-t was 453304.68 ± 124424.94 (h*ng/mL), Cmax was (2634.03 ± 833.82)ng/mL; The main pharmacokinetic parameters of reference Etanercept were as follows: AUC0-∞ was 537977.72 ± 153295.70 (h*ng/mL), AUC0-t was 528817.19 ± 150910.05 (h*ng/mL), Cmax was (2874.21 ± 822.31) ng/mL.","QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200659/),[ng] / [ml],2634.03,272139,DB00005,Etanercept
,32200659,AUC0-∞,"The main pharmacokinetic parameters of QL0902 were as follows: AUC0-∞ was 461861.60 ± 126861.42 (h*ng/mL), AUC0-t was 453304.68 ± 124424.94 (h*ng/mL), Cmax was (2634.03 ± 833.82)ng/mL; The main pharmacokinetic parameters of reference Etanercept were as follows: AUC0-∞ was 537977.72 ± 153295.70 (h*ng/mL), AUC0-t was 528817.19 ± 150910.05 (h*ng/mL), Cmax was (2874.21 ± 822.31) ng/mL.","QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200659/),[h·ng] / [ml],537977.72,272140,DB00005,Etanercept
,32200659,AUC0-t,"The main pharmacokinetic parameters of QL0902 were as follows: AUC0-∞ was 461861.60 ± 126861.42 (h*ng/mL), AUC0-t was 453304.68 ± 124424.94 (h*ng/mL), Cmax was (2634.03 ± 833.82)ng/mL; The main pharmacokinetic parameters of reference Etanercept were as follows: AUC0-∞ was 537977.72 ± 153295.70 (h*ng/mL), AUC0-t was 528817.19 ± 150910.05 (h*ng/mL), Cmax was (2874.21 ± 822.31) ng/mL.","QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200659/),[h·ng] / [ml],528817.19,272141,DB00005,Etanercept
,32200659,Cmax,"The main pharmacokinetic parameters of QL0902 were as follows: AUC0-∞ was 461861.60 ± 126861.42 (h*ng/mL), AUC0-t was 453304.68 ± 124424.94 (h*ng/mL), Cmax was (2634.03 ± 833.82)ng/mL; The main pharmacokinetic parameters of reference Etanercept were as follows: AUC0-∞ was 537977.72 ± 153295.70 (h*ng/mL), AUC0-t was 528817.19 ± 150910.05 (h*ng/mL), Cmax was (2874.21 ± 822.31) ng/mL.","QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32200659/),[ng] / [ml],2874.21,272142,DB00005,Etanercept
